Capricor Therapeutics is a pre-revenue biotechnology company with a complete cessation of commercial sales, as evidenced by -100.0% revenue growth in 2025Q4. The investment thesis hinges on the successful development and commercialization of its pipeline, part...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.70-18.9% vs -$0.59 | — vs $2M |
Q3 2026 Aug 13, 2026 | -$0.70-18.9% vs -$0.59 | — vs $2M |
Q3 2026 Aug 11, 2026 | -$0.70-18.9% vs -$0.59 | — vs $2M |
Q2 2026 May 12, 2026 | -$0.59-7.3% vs -$0.55 | — vs $40M |
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRPR NewswireNEW YORK, Sept. 28, 2026NEW Y
SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").
New York, New York--(Newsfile Corp. - September 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us.
NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us.
Benchmark CAPR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Capricor Therapeutics, Inc. (CAPR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.95 | $514.72M | -3.96 | -100% | — | -46.56% | — | |
| $17.50 | $1.85B | -2.45 | 15.58% | -6.93% | -9.96% | — | |
| $55.43 | $5.35B | -8.57 | -89.97% | -3368.72% | -24.39% | — | |
| $58.39 | $14.68B | 21.00 | 6.98% | 35.33% | 42.49% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $15.22 | $1.5B | -2.61 | 20.13% | -81.79% | — | — |
Capricor Therapeutics, Inc. (CAPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Capricor Therapeutics, Inc. (CAPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 24, 2026·SEC
Aug 13, 2026·SEC
Jul 30, 2026·SEC
Get notified when CAPR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Capricor Therapeutics, Inc. (CAPR) stock FAQ — growth, dividends, profitability & financials explained
Capricor Therapeutics, Inc. (CAPR) saw revenue decline by 100.0% over the past year.
Capricor Therapeutics, Inc. (CAPR) reported a net loss of $129.4M for fiscal year 2025.
Capricor Therapeutics, Inc. (CAPR) has a return on equity (ROE) of -46.6%. Negative ROE indicates the company is unprofitable.
Capricor Therapeutics, Inc. (CAPR) had negative free cash flow of $129.8M in fiscal year 2025, likely due to heavy capital investments.
